Pandey Kailash N
Department of Physiology, Tulane University School of Medicine and Health Sciences Center, New Orleans, LA 70112, USA.
Mol Cell Biochem. 2002 Jan;230(1-2):61-72.
Atrial natriuretic peptide (ANP) is the first described member of the natriuretic peptide hormone family. ANP elicits natriuretic, diuretic, vasorelaxant and antiproliferative effects, important factors in the control of blood pressure homeostasis. One of the principal loci involved in the regulatory action of ANP is the guanylyl cyclase-linked ANP-receptor which has been designated as NPRA, also referred to as GC-A, whose ANP-binding efficiency and guanylyl cyclase activity vary remarkably in different target tissues. However, the cellular and molecular basis of these activities and the functional expression and regulation of NPRA are not well understood. The mature form of receptor resides in the plasma membrane and consists of an extracellular ligand-binding domain, a single transmembrane-spanning region, and intracellular protein kinase-like homology and guanylyl cyclase catalytic domains. In this review, emphasis has been placed on the interaction ofANP with NPRA, the ligand-mediated endocytosis, trafficking, and subcellular distribution of ligand-receptor complexes from cell surface to the intracellular compartments. Furthermore, it is implicated that after internalization, the ANP/NPRA complexes dissociate into the subcellular compartments and a population of receptor recycles back to the plasma membrane. This is an interesting area of research in the natriuretic peptide receptor field because there is currently debate over whether ANP/NPRA complexes internalize at all or whether cell utilizes some other mechanisms to release ANP from the bound receptor molecules. Indeed, controversy exist since it has been previously reported by default that among the three natriuretic peptide receptors only NPRC internalizes with bound ligand. Hence, from a thematic standpoint it is clearly evident that there is a current need to review this subject and provide a consensus forum that establishes the cellular trafficking, sequestration and processing of ANP/NPRA complexes in intact cells. Towards this aim the cellular life-cycle of NPRA will be described in the context ofANP-binding, internalization, metabolic processing, and/or inactivation, down-regulation, and degradation of ligand-receptor complexes in model cell systems.
心房利钠肽(ANP)是利钠肽激素家族中首个被描述的成员。ANP具有利钠、利尿、血管舒张和抗增殖作用,是控制血压稳态的重要因素。参与ANP调节作用的主要位点之一是与鸟苷酸环化酶相连的ANP受体,该受体被命名为NPRA,也称为GC-A,其ANP结合效率和鸟苷酸环化酶活性在不同靶组织中差异显著。然而,这些活性的细胞和分子基础以及NPRA的功能表达和调节尚未完全清楚。受体的成熟形式位于质膜上,由细胞外配体结合域、单个跨膜区以及细胞内蛋白激酶样同源性和鸟苷酸环化酶催化域组成。在本综述中,重点关注了ANP与NPRA的相互作用、配体介导的内吞作用、配体-受体复合物从细胞表面到细胞内区室的运输和亚细胞分布。此外,有迹象表明,内化后,ANP/NPRA复合物在亚细胞区室中解离,一部分受体会循环回到质膜。这是利钠肽受体领域一个有趣的研究方向,因为目前关于ANP/NPRA复合物是否完全内化,或者细胞是否利用其他机制从结合的受体分子中释放ANP存在争议。事实上,存在争议是因为此前默认报道称,在三种利钠肽受体中,只有NPRC会与结合的配体内化。因此,从主题角度来看,显然目前需要对该主题进行综述,并提供一个共识论坛,以确定完整细胞中ANP/NPRA复合物的细胞运输、隔离和处理过程。为了实现这一目标,将在模型细胞系统中结合ANP结合、内化、代谢处理和/或失活、下调以及配体-受体复合物降解的背景下描述NPRA 的细胞生命周期。